(358) Exposure-Safety Analyses of Talazoparib in Combination With Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in TALAPRO-2 Trial
To characterize the relationship between talazoparib exposure and selected safety endpoints including grade 3 and higher (Gr⩾3) anemia, neutropenia, and thrombocytopenia, and to identify potential prognostic factors for these safety endpoints in patients with mCRPC in the TALAPRO-2 study (NCT03395197)
Learning Objectives:
To characterize the relationship between talazoparib exposure and selected safety endpoints including grade 3 and higher (Gr⩾3) anemia, neutropenia, and thrombocytopenia, and to identify potential prognostic factors for these safety endpoints in patients with mCRPC in the TALAPRO-2 study (NCT03395197)